Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 356 publications
Older Age, STAG2, and DNMT3A Mutations Predict Superior Posttransplant Survival in Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents.
Journal: American journal of hematology
Published: July 11, 2026
ICC/WHO-Defined and NGS-Annotated Idiopathic Hypereosinophilia (iHES/iHE): Mutations, Clinical and Treatment Details, and Predictors of Survival.
Journal: American journal of hematology
Published: June 03, 2026
Determinants of survival after failure of frontline venetoclax plus hypomethylating agent therapy in 356 patients with newly diagnosed acute myeloid leukemia.
Journal: Blood cancer journal
Published: May 27, 2026
Systemic Mastocytosis in Adults: 2026 Update on Diagnosis, Risk Stratification and Management.
Journal: American journal of hematology
Published: May 20, 2026
Distinct Longitudinal Patterns of Basal and Squamous Cell Carcinoma in Polycythemia Vera and Essential Thrombocythemia.
Journal: American journal of hematology
Published: May 20, 2026
Acute Myeloid Leukemia Subtype-Specific Prognostic Value of NGS in the Setting of Intensive Chemotherapy.
Journal: American journal of hematology
Published: May 13, 2026
Autoimmune and Inflammatory Diseases in Polycythemia Vera and Essential Thrombocythemia: Impact on Disease Outcomes and Comorbidities.
Journal: American journal of hematology
Published: April 08, 2026
Risk-Adjusted Comparison of Survival in Chronic Myelomonocytic Leukemia With and Without Allogeneic Stem Cell Transplant: Mayo Clinic Experience in 775 Consecutive Patients.
Journal: American journal of hematology
Published: March 30, 2026
Cancer history and second cancer risk in polycythemia vera and essential thrombocythemia.
Journal: Blood cancer journal
Published: March 30, 2026
Next generation sequencing panel for hereditary erythrocytosis in adults with otherwise unexplained erythrocytosis unveils additional genomic variants.
Journal: Haematologica
Published: January 15, 2026
One vs. 2 vs. ≥3 TET2 mutations in chronic myelomonocytic leukemia: co-mutation patterns and prognostic relevance in the context of contemporary prognostic models including BLAST-mol and CPSS-mol.
Journal: Blood cancer journal
Published: January 12, 2026
CPX-351 (Liposomal Cytarabine and Daunorubicin) versus venetoclax plus hypomethylating agent therapy in newly diagnosed acute myeloid leukemia: a retrospective comparison involving 600 Mayo Clinic patients.
Journal: Blood cancer journal
Published: November 28, 2025
Last Updated: 09/26/2026